Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson’s disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca) and protein (α-syn). Effects of β2AR agonist clenbuterol on the levels of Snca mRNA and α-syn protein we...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Joseph R., Hirst, Warren D., Howe, Jacob W., Russell, Christopher P., Cole-Strauss, Allyson, Kemp, Christopher J., Duffy, Megan F., Lamp, Jared, Umstead, Andrew, Kubik, Michael, Stoll, Anna C., Vega, Irving E., Steece-Collier, Kathy, Chen, Yi, Campbell, Anne C., Nezich, Catherine L., Glajch, Kelly E., Sortwell, Caryl E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130326/
https://www.ncbi.nlm.nih.gov/pubmed/35610264
http://dx.doi.org/10.1038/s41531-022-00322-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130326/
https://www.ncbi.nlm.nih.gov/pubmed/35610264
http://dx.doi.org/10.1038/s41531-022-00322-x

Ejemplares similares